Here are four things to know about the record-breaking period.
1. During the same period of 2017, seven $5 billion-plus deals were unveiled, according to Dealogic.
2. The cumulative value of the deals announced within the period is $207 billion. This is the highest amount since 2000 for the same period, according to the report.
3. Fast-paced dealmaking follows recent U.S. tax reform, which lowered the corporate tax rate from 35 percent to 21 percent.
Curt Moldenhauer, a partner at PricewaterhouseCoopers’ deals practice, told The Wall Street Journal, “January is only the beginning of what we see as a very robust 2018. Certainly with tax reform being announced, a big piece of the puzzle was solved.”
4. Some of the big deals include Sanofi’s $11.6 billion bid to acquire all outstanding shares of U.S. hemophilia drugmaker Bioverativ and biopharmaceutical giant Celgene’s $9 billion purchase of Juno Therapeutics.
More articles on business:
Study predicts Amazon will pick Atlanta for its HQ2
Big tech spent $50M on lobbying last year
Tesla aims for $650B valuation in new compensation plan for CEO Elon Musk
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
